https://www.statcounter.com/counter/counter.js
Web Analytics
Home » 2019 » April
Imbed Biosciences secures financing for MicroLyte Ag Antimicrobial Matrix

Imbed Biosciences secures financing for MicroLyte Ag Antimicrobial Matrix

Imbed Biosciences, a Wisconsin-based medical device company, development of advanced therapies for soft tissue repair, has raised $2 million in a Series A financing round. The proceeds from the financing round are expected to help the medical device company commercialize its FDA-approved MicroLyte Ag Antimicrobial Matrix, which is indicated for the management of burns, chronic […]

Wayne Pharmaceuticals launches Dr Wayne’s Aspirin in US

Wayne Pharmaceuticals has launched Dr Wayne’s Aspirin Tablets in the US in a bottle package containing 300 tablets, each having 81mg strength. Dr. Wayne’s Aspirin is an enteric-coated tablet which does not upset the stomach. Aspirin tablets are mainly used to lower the stroke risk in persons who had a mini-stroke (transient ischemic attack) or […]

Continue reading …
Dr Reddy’s Laboratories to acquire generic injectable products in the US

Dr Reddy’s Laboratories has agreed to acquire a portfolio of 42 approved, non-marketed abbreviated new drug applications (ANDAs) in the US, which includes more than 30 generic injectable products, from an undisclosed seller. The generic injectable products would need technology transferred and may be launched within 1-2 years. According to IQVIA, the value of the […]

Continue reading …
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

Continue reading …
Novartis to acquire IFM Tre with eye on immunomodulatory drugs

Novartis acquisition of IFM Tre : Novartis has signed a deal worth up to $1.575 billion to acquire US biopharma company IFM Tre from IFM Therapeutics. Novartis acquisition of IFM Tre The acquisition of the US biopharma company, which was only launched last year, is expected to add certain immunomodulatory drugs to the Swiss pharma […]

Continue reading …
Ethicon wraps up $3.4bn acquisition of robotic medical company Auris Health

Ethicon acquisition of Auris Health : Johnson & Johnson’s subsidiary Ethicon has wrapped up its previously announced $3.4 billion acquisition of California-based robotic medical company Auris Health. Ethicon acquisition of Auris Health Based on the achievement of certain predetermined milestones, the deal will see additional contingent payments made by Ethicon worth up to $2.35 billion. […]

Continue reading …
US CDMO Brammer Bio to be acquired by Thermo Fisher

Thermo Fisher acquisition of Brammer Bio : Thermo Fisher Scientific, a global life sciences company, has agreed to buy US-based viral vector contract development and manufacturing organization (CDMO) Brammer Bio for $1.7 billion in an all-cash transaction. Thermo Fisher acquisition of Brammer Bio Brammer Bio, which is owned by Ampersand Capital Partners, is focused on […]

Continue reading …
Italian CDMO Olon wraps up acquisition of Mahad API plant in India

Mahad API plant acquisition : Olon, an Italy-based active pharmaceutical ingredients (API) developer and manufacturer, has completed the acquisition of an API manufacturing facility in Mahad in Maharashtra, India. The company’s subsidiary Olon India will initiate all the activities the next April 1st as per the strategy of Olon after an intensive transition period that […]

Continue reading …
Lilly teams up with ImmuNext for developing drugs for autoimmune diseases

US pharma giant Eli Lilly and Company (Lilly) and Lebanon-based ImmuNext have announced a global licensing and research collaboration for the development of drugs for the treatment of autoimmune diseases. Under the partnership, the two pharma companies will focus on the study of a preclinical target that could lead to potential new drugs for autoimmune […]

Continue reading …
Arch Oncology raises $50m to advance anti-CD47 antibody therapies

Pharma industry news : Arch Oncology, a California-based clinical-stage immune-oncology company, has raised a funding of $50 million in a Series B financing round. The immune-oncology company is engaged in the discovery and development of anti-CD47 antibody therapies. The new capital will enable Arch Oncology to advance the ongoing phase 1 clinical trial of its […]

Continue reading …
Page 1 of 212